McMaster researchers report EVT0185 may prevent and reverse liver fibrosis by targeting metabolism, offering a promising therapy for MASH with clinical trials expected by 2027.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
